Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT01938261 |
| Other study ID # |
100-2013 |
| Secondary ID |
2013-001842-33 |
| Status |
Recruiting |
| Phase |
Phase 2
|
| First received |
|
| Last updated |
|
| Start date |
August 2013 |
| Est. completion date |
September 2024 |
Study information
| Verified date |
January 2024 |
| Source |
University of Oulu |
| Contact |
Outi Aikio, M.D., Ph.D. |
| Phone |
+358 8 3155810 |
| Email |
outi.aikio[@]pohde.fi |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Present randomized, controlled, double-blind trial investigates the efficacy and safety of
early (<24 h) intravenous paracetamol therapy for pain medication in very small premature
infants. This phase 2 drug study focuses on the efficacy and safety of short-term use. The
pharmacokinetics and pharmacodynamics of paracetamol, as well as the long-term effects, are
studied.
This study recruits preterm infants born less than 32 weeks gestational age and treated at
the neonatal intensive care unit of Oulu University Hospital. The informed consent is asked
from all parents. The first drug dose is given before 24 hours of age. Masked study drug is
paracetamol infusion solution 10 mg/mL or placebo, 0.45% saline solution. The loading dose is
20 mg/kg, and the maintenance dose 7.5 mg/kg every 6 hours for 4 days. The exact date of the
closure of ductus is studied by repeated echocardiographic examinations. The symptoms of pain
are screened by a pain scale of preterm infants (NIAPAS). Patients are monitored for signs of
possible side effects. After discharge from hospital, patients are examined at follow-up
clinic for the first year every 3 months and at 2 years of age.
Description:
1 Hypotheses and aims: The aim of the present study is to evaluate the safety and efficacy of
intravenous paracetamol in pain medication for small preterm infants in a randomized,
controlled, double-blind trial. The primary outcome of the pain medication arm is the need
for morphine medication (doses). The secondary outcomes are paracetamol serum concentrations,
the side effects of paracetamol (possible hepatic dysfunction), neonatal and long-term
morbidity, and mortality.
The primary outcome in the phase 2 ductus study-arm was diminishing of the ductal caliber at
5 days postnatal age. This study arm has been finalized and the results were published on
2016 (Härkin et al).
Hypotheses:
I. Hypothesis. Early, intravenous paracetamol is effective and safe therapy in the relief of
pain and discomfort of a preterm infant.
II. Hypothesis. Paracetamol levels of a preterm infant remain in safety limits with study
dosages.
III. Hypothesis. Early, intravenous paracetamol does not increase long-term morbidity in
preterm infants.
Objectives:
1. Aim: to evaluate in a randomized, controlled, double-blind trial, the efficacy and
safety of the early (<24 h), intravenous paracetamol in pain treatment of a preterm
infant.
2. Aim: to evaluate the safety of the early (<24 h), intravenous paracetamol in preterm
infants requiring intensive care.
3. Aim: to study pharmacokinetics and pharmacodynamics of paracetamol in a preterm infants
4. Aim: to evaluate the long-term effects of the early (<24 h), intravenous paracetamol in
preterm infants requiring intensive care.
2 Study permissions: The research plan is registered to the investigational diary of the
Department of Pediatrics, Oulu University Hospital (diary number 100-2013). For the present
trial, the permissions from The Northern Ostrobothnia Hospital district's Ethical Board and
Oulu University Hospital's administrative officials have been applied and granted. The study
permission has been applied and granted from Fimea, the Finnish Medicines Agency. The
amendment of the research plan was approved on 30.4.2018. This project has been assigned to
EudraCT network (European Clinical Trials Database), Eudra CT number 2013-008142-33, and the
international ClinicalTrials.gov registry, identification number NCT01938261.
Written informed consent is asked by the primary investigators of the study from all study
patients' parents. The present clinical trial is managed by the principles of Good Clinical
Practice, GCP (Fimea, act 2/2012, Clinical drug trials). The essential changes of the
research plan are announced to Fimea according to the Drug legislation act 87a, using the
European commission internet site (http://ec.europa.eu/health/documents/eudralex/vol-10/).
3 Sample size: The sample size calculation for the pain medication trial was checked after
the first randomization. According to our previous study (Härmä et al, 2016), non-exposed
premature infants received approximately 5 doses of morphine (SD 12) during their stay in the
NICU. In order to treat infants without opioids, the clinical difference was approximated to
be 6 doses. Therefore, with 20% power and 0.05 alpha-error, 126 infants (63/group) were
required.
4 Study patients and exclusion criteria: This study will recruit all the intubated premature
infants born less than 32 weeks of gestational age managed in Oulu University Hospital's
neonatal intensive care unit. The deadline for recruitment and administration of the first
dose of the study drug is postnatal age of 24 hours. The study exclusion criteria are severe
structural, or chromosomal abnormality, and other severe clinical situation, which
essentially affects the small premature infants' conventional early-stage treatment, e.g.
severe asphyxia or persistent pulmonary hypertension (PPHN).
5 Randomization and blinding: As the informed consent is given, the study patient receives a
trial number from the list made prior to the entry of the study. The trial number will match
with an envelope where has been drawn a leaflet with the patient's study medication group
written on it. Placebo, 0.45 % saline, is similar to paracetamol, both being clear liquids,
so the staff will remain unaware which drug the patient receives. The study medication will
be kept and prepared at the ward 55 in a separate office, in a locked cabinet. The study drug
will be prepared by the study nurse, or by a nurse who does not participate in the study
patients' treatment in any way.
6 Intervention: Masked study drug is 10 mg/ml paracetamol solution (Paracetamol Kabi
Pharmacia®). Placebo is 0.45% saline solution, which does not enhance the potential small
preterm infants' early-stage hypernatremia or hyperglycemia. Both are visually similar, clear
solutions. Loading dose, 20 mg/kg, is followed by a maintenance dose 7.5 mg/kg every 6 hours,
for four days. According to the earlier phase 1 studies, this dose is considered to be safe
for small preterm infant. The drug is administered as a 15-minute infusion. No other
paracetamol preparations are allowed to be given simultaneously with the study drug. After
the intervention, the use of paracetamol should be restricted as far as it is possible. If
the patient's clinical condition requires starting of paracetamol medication, there should be
at least two days absence of paracetamol after the last dose of study medication. Half-life
of intravenous paracetamol in neonates is about 4.5 hours. No other restrictions on the
patient's therapy are set. After the study intervention, the patient is treated by the
attending physicians' clinical judgment. Whenever necessary, the patient will be given the
normal dose of morphine, 0.1 mg/kg.
6.1 Monitoring of the pain symptoms: The pain or discomfort of the patients will be screened
using NIAPAS scoring before and after the study drug administration. According to the NIAPAS
guidelines, values >5 indicate the need for evaluation for pain relief, either with using the
non-medical pain relief methods, or increasing the pain medication dose. All the study
patients will receive necessary pain medication during the study which would be morphine ad
0.1 mg/kg single doses, or morphine infusion. All morphine doses given during and after the
intervention are recorded and calculated as the cumulative dosage.
7 Paracetamol safety: Using the study drug dosage, no signs of liver or renal failure have
been described before. In addition, in the recent retrospective analysis among the study unit
patient population, none of the preterm infants who received paracetamol showed any clinical
or laboratory signs of either complication. No increased levels of liver transaminases,
bilirubin or creatinine were detected.
In paracetamol intoxication, the hepatic failure is caused by a paracetamol metabolite, not
paracetamol itself. Thus, the symptoms of intoxication are not immediately evident. The
hepatic tissue damage can be prevented administering the paracetamol antidote as soon as
possible. Even a suspicion of a possible intoxication in an otherwise symptom-free patient is
to be taken seriously. This situation should be cautiously clarified, and, if necessary, the
antidote started vigorously.
The signs and symptoms of paracetamol intoxication include:
- During the first 24 hours, nausea, vomiting, loss of appetite, fatigue, and perspiration
may be manifested.
- 24-48 h after the overdose, the signs of it may be seen in the laboratory examinations:
bilirubin and hepatic transaminase levels increase, and the prothrombin time lengthens
(INR increases; this may happen without hepatic failure if the synthesis of vitamin K
dependent coagulation factors is inhibited). Diuresis may be diminished due to possible
dehydration (vomiting), renal failure, and the antidiuretic action of paracetamol.
- 2-5 days later, the liver and renal tissue damage develops. In the patients with hepatic
failure, metabolic acidosis is usually seen.
Early acetyl cysteine therapy (<16 h after the overdose) may inhibit the hepatic failure, but
even when started later, the tissue damage may be restricted. If necessary, the Poison
Information Centre is consulted about the individualized instructions for treatment. The
initial treatment includes intravenous fluid therapy in order to correct the acidosis, and
the goal for the diuresis would be >1.5 ml/kg/h. The intravenously administered study
medication cannot cause any harmful effects to the patients' relatives, the hospital staff,
or the environment.
8 Monitoring, reporting and follow-up of the possible side effects: All study patients will
be monitored for signs of possible side effects, especially the signs of hepatic or renal
dysfunction. During the first postnatal days, serum bilirubin levels and diuresis will be
followed. If a patient had prolonged or otherwise pronounced jaundice, the abdominal
ultrasound would be performed. Any evidence of hepatic or renal dysfunction would be an
indication to withdraw the study medication, and to measure the hepatic transaminases and
creatinine concentrations. Symptomatic hepatic or renal failure is defined as an emergency
when the blinding code could be opened and the study discontinued.
All harmful events and suspected side effects are individually evaluated for possible
association to the study drug. The associations are classified: certain - likely - unlikely -
not possible. The harmful events that are classified significant (SUSAR) are listed by the
responsible investigator. Of the serious and unexpected harmful events, death or mortal
danger are announced to Fimea within seven days after the incidence and the others within 15
days. The list of the harmful events is delivered to Fimea every year.
9 Pharmacokinetics: From those study patients with an arterial cannula, a single 1 ml blood
sample at 48 hours postnatal age will be collected to evaluate paracetamol serum
concentrations and the biological effects of prematurity. Of all the routine blood samples,
any remaining droplets are retained for paracetamol concentration measurements.
10 Data collection: The study data will be collected using Centricity Critical Care Clinisoft
software (GE Healthcare). All the data is confidential. All the study personnel are involved
with confidentiality. The computed data is collected into the hospital's intranet station O.
Study papers are mapped, and kept in the room of the responsible investigator. The Office of
the Data Protection Ombudsman has been informed about the study register. The study results
will be published in international, peer-reviewed medical literature, and in medical theses.
11 Quality control: An external study monitor, observing the quality of the methods used and
the fulfillment of the study patients' rights, has been named.
12 Long-term follow-up: For the first year after discharge from hospital, the patients will
be examined every three months at the follow-up clinic. Patients will be examined the
clinical status, basic laboratory parameters, and if necessary, radiographic studies.
13 Statistical analyses: The intention-to-treat principle is applied in all analyzes. P-value
<.05 will be considered significant. Statistical analyzes will be made using the IBM SPSS
software.
